Actively Recruiting

Phase Not Applicable
Age: 22Years +
MALE
NCT05574868

Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis (ERASE ED)

Led by Rigicon, Inc. · Updated on 2025-12-05

182

Participants Needed

7

Research Sites

201 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study evaluates the long-term safety and efficacy of the use of the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis in patients with erectile dysfunction. This study follows patients implanted with the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for up to 3 years after implantation. This study will take approximately 6 months to enroll all subjects. (14 days, 6 weeks, 6 months, 12 months,18 months, 24 months, and 36 months, post-procedure. ) Subjects will be followed per protocol and institutional standard of care for ED and comorbidities.

CONDITIONS

Official Title

Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis (ERASE ED)

Who Can Participate

Age: 22Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male 22 years of age or older
  • Diagnosed with erectile dysfunction (impotence)
  • Agree to receive Infla10�ae three-piece inflatable penile prosthesis as ED treatment
  • Willing to complete all required follow-up visits and tests
Not Eligible

You will not qualify if you...

  • Contraindication to general anesthesia
  • Known allergy or sensitivity to device materials
  • Previous penile prosthesis or prior enlargement surgeries
  • Diagnosed penile sensory neuropathy
  • Fibrotic diseases such as priapism, Peyronie's disease, or Chordee
  • Compromised immune system (e.g., lupus, scleroderma)
  • Receiving immunosuppressive drugs or history of kidney transplant
  • Uncontrolled diabetes (FBS >300 or HbA1c 9.0 on surgery day)
  • Bleeding disorder or coagulopathy preventing safe procedure
  • Active urogenital, skin, or systemic infection at assessment
  • Significant or unstable comorbidities affecting safety or study results
  • Cognitive disorders affecting communication or questionnaire completion
  • Lacking manual dexterity or mental ability to operate the device
  • Expected life expectancy less than two years
  • Unwilling or unable to sign informed consent
  • Unwilling or unable to comply with follow-up requirements
  • Currently in another investigational drug or device study
  • Incarcerated individuals
  • Psychogenic erectile dysfunction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Wesley Hospital

Auchenflower, Australia

Actively Recruiting

2

Canberra Laparoscopic, Robotic & Laser Urology Centre

Garran, Australia

Actively Recruiting

3

Katelaris Urology

Hornsby, Australia

Actively Recruiting

4

St George Urology

Hurstville, Australia

Actively Recruiting

5

Advanced Urology Melbourne

Malvern, Australia

Actively Recruiting

6

Shire Urology

Miranda, Australia

Actively Recruiting

7

Urology South at Holmesglen Private Hospital

Moorabbin, Australia

Actively Recruiting

Loading map...

Research Team

Z

Zeynep Tin Konukcu

CONTACT

F

Feyzanur CALDIRAN, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here